Laboratory Guide to Semaglutide Testing and Analysis

Semaglutide has expanded far beyond its origins as a diabetes medication. What began as a once-weekly injectable GLP-1 receptor agonist for type 2 diabetes (Ozempic, approved 2017) has evolved into a multi-formulation, multi-indication therapeutic platform with three commercially marketed products: Ozempic (injectable, diabetes + cardiovascular + CKD), Wegovy (injectable, obesity + cardiovascular + MASH), and Rybelsus (oral tablet, diabetes + cardiovascular + obesity). As of April 2026, semaglutide is the most commercially successful pharmaceutical product in history by sales, and its clinical indication expansion continues.

Each formulation presents distinct analytical testing challenges. The injectable products are manufactured by Novo Nordisk using recombinant DNA technology in yeast — not synthetic peptide synthesis — a distinction with profound quality implications that separates the approved products from all compounded versions. Rybelsus requires analysis of SNAC, its unique oral absorption enhancer. The scale of semaglutide’s clinical development has generated a rich bioanalytical literature. And the period of widespread compounding (2022–2025) produced both quality data revealing how compounded synthetic semaglutide differs from the recombinant branded product and a regulatory response that has fundamentally ended routine compounding.

For pharmaceutical manufacturers, CROs, research organizations, and testing laboratories, this guide provides the complete analytical testing framework for semaglutide across all three formulations — from drug substance characterization through bioanalytical method development, injectable safety testing, stability, and immunogenicity. Submit a testing request to find an accredited laboratory for your semaglutide testing needs.

Semaglutide Products and Approved Indications (2026)

Understanding the full semaglutide product landscape is essential context for any testing program — each product’s formulation, delivery system, and indication influences which tests are required.

Brand	Formulation / route	Approval year	FDA-approved indications
Ozempic	Injectable SC 0.5, 1, 2 mg once weekly	2017 (T2D), 2020 (CV), 2025 (CKD)	(1) Improve glycemic control in adults with T2D; (2) Reduce risk of MACE (CV death, MI, stroke) in adults with T2D and established CV disease; (3) Reduce risk of kidney disease worsening, kidney failure, and CV death in adults with T2D and CKD (Jan 2025, FLOW trial)
Wegovy	Injectable SC 2.4 mg once weekly	2021 (obesity), 2022 (adolescents), 2024 (CV), 2025 (MASH)	(1) Chronic weight management in adults and adolescents >/=12 years with obesity or overweight + comorbidity; (2) Reduce risk of MACE in adults with established CV disease and obesity or overweight (Mar 2024, SELECT trial: 20% MACE reduction); (3) MASH with moderate-to-advanced liver fibrosis (accelerated approval, Aug 2025)
Rybelsus	Oral tablet 3, 7, 14 mg (diabetes); 25 mg (obesity) once daily	2019 (T2D), 2024 (CV), 2025 (obesity)	(1) Improve glycemic control in adults with T2D (2019, first oral GLP-1 RA); (2) Reduce risk of MACE in adults with T2D and established ASCVD or CKD (Oct 2024, SOUL trial: 14% MACE reduction); (3) Chronic weight management in adults with obesity or overweight (Dec 2025)

Semaglutide: Structural Properties and Analytical Implications

Injectable semaglutide structure

Semaglutide is a 31-amino acid GLP-1 receptor agonist (molecular weight approximately 4,113.58 Da) derived from native human GLP-1(7-36) amide by three targeted structural modifications designed to extend half-life and resist enzymatic degradation:

• Aib8 (alpha-aminoisobutyric acid at position 8): Replaces the alanine residue at position 8, conferring resistance to DPP-4 (dipeptidyl peptidase-4) cleavage — the primary degradation pathway for native GLP-1. This substitution is critical for the extended half-life.
• Lys34 to Arg34 substitution: Removes the second lysine residue that would otherwise compete as an acylation site, directing the C18 fatty acid modification exclusively to Lys26.
• C18 fatty diacid at Lys26 via gamma-glutamic acid-mini-PEG linker: A C18 fatty diacid moiety is attached to the epsilon-amino group of Lys26 through a short linker. This enables reversible, non-covalent binding to serum albumin, which is the primary mechanism extending semaglutide’s half-life to approximately 165-183 hours in humans — sufficient for once-weekly subcutaneous dosing.

The C18 fatty acid modification creates the same analytical challenge as tirzepatide: standard 100-130 angstrom pore reversed-phase columns used for smaller peptides produce poor peak shape and inadequate resolution for the lipidated molecule. Wide-pore stationary phases — specifically 300 angstrom pore PLRP-S polymer columns or wide-pore C18/C4 silica — are required for acceptable chromatographic separation. Method development must also address the sensitivity of semaglutide retention to pH (optimal stability at pH 7.4-7.8 per formulation data; HPLC methods typically use acidic mobile phases at ~pH 2 with TFA) and ion-pairing reagent selection.

For LC-MS/MS bioanalysis, semaglutide produces multiple charge states in positive electrospray ionization. The dominant precursor ion is [M+4H]4+ at m/z 1029.3, with [M+5H]5+ also observed. Validated plasma bioanalysis methods achieve LLOQ of approximately 0.1-1 ng/mL with a dynamic range to 100-1000 ng/mL, using Peptide CSH C18 columns and acetonitrile/formic acid gradients. Liraglutide is commonly used as an internal standard due to structural similarity.

Critical manufacturing distinction: recombinant vs. synthetic semaglutide

This is the most important analytical distinction specific to semaglutide and has no parallel in tirzepatide testing. Novo Nordisk manufactures Ozempic, Wegovy, and Rybelsus using recombinant DNA technology in Saccharomyces cerevisiae yeast — the same fermentation-based production platform used for biopharmaceuticals, not the solid-phase peptide synthesis (SPPS) used to manufacture tirzepatide and virtually all compounded GLP-1 products.

This manufacturing difference has profound quality implications:

• Impurity profile: Recombinant yeast-expressed semaglutide has a characteristic fermentation-related impurity profile — host cell proteins (HCPs), host cell DNA, and process-related impurities from fermentation. Synthetic SPPS semaglutide has synthesis-related impurities: deletion sequences, amino acid substitution variants, incomplete coupling products, and diastereomers. These two impurity profiles are fundamentally different and cannot be compared using the same reference standards or analytical methods.
• Molecular characteristics: The yeast expression system imparts specific folding characteristics and molecular properties. Novo Nordisk’s research demonstrated that synthetically produced semaglutide and Novo Nordisk’s recombinantly expressed semaglutide have different physical and chemical stability profiles that could affect drug product stability and performance.
• Regulatory implications: These differences formed the basis of Novo Nordisk’s formal petition nominating semaglutide for the FDA’s ‘Demonstrable Difficulties for Compounding’ (DDC) lists — arguing that the complexity of replicating recombinant semaglutide through synthetic compounding makes it inherently unsuitable for routine compounding. Independent testing confirmed compounded synthetic semaglutide samples with synthesis-related impurities not found in the Novo Nordisk branded products.

For analytical testing, this means: RP-HPLC and LC-MS/MS methods developed and validated against Novo Nordisk’s recombinant semaglutide reference standards may not fully characterize impurities in synthetically produced samples, and vice versa. Full characterization of compounded semaglutide requires methods capable of detecting both synthesis-related impurities and reference to specifications appropriate for synthetic production.

Rybelsus: oral semaglutide and SNAC

Rybelsus (oral semaglutide) contains the same semaglutide molecule as the injectable products but co-formulated with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) — a novel absorption enhancer that enables GI uptake of this large, lipophilic peptide. SNAC works primarily by locally increasing pH in the stomach mucosa, protecting semaglutide from acidic degradation and facilitating transcellular absorption through the gastric epithelium. Oral semaglutide bioavailability is approximately 0.8% in humans, compared to approximately 89% for subcutaneous injection — requiring much higher oral doses (3-25 mg oral vs. 0.25-2.4 mg injectable) to achieve equivalent plasma exposures.

The SNAC co-formulation creates distinct analytical requirements for Rybelsus testing compared to the injectable products:

• SNAC quantification: SNAC must be measured separately from semaglutide in finished product release testing, using HPLC or LC-MS methods validated against SNAC reference standards. The SNAC molecule itself requires characterization for identity, purity, and specification compliance.
• Oral bioanalysis complexity: Bioanalytical methods for oral semaglutide pharmacokinetic studies must account for the much lower plasma concentrations achieved after oral dosing and potential interference from SNAC or its metabolites. More sensitive analytical platforms (LLOQ <0.5 ng/mL) are required vs. injectable bioanalysis.
• Stability in oral formulation: The SNAC formulation places semaglutide in close proximity to the excipient at potentially varying pH conditions during storage and GI transit. Stability studies must assess the semaglutide-SNAC system under ICH Q1A conditions and confirm the absence of covalent modification or degradation driven by the formulation conditions.

Critical Regulatory Update: Semaglutide Compounding Status (2025-2026)

IMPORTANT NOTE FOR EDITORS: This section addresses the compounding landscape that existed at the time of original publication (Aug 2024) and has since entirely changed. The article was written during the active shortage period; that period has ended.

Complete timeline of semaglutide compounding regulation through April 2026:

• March/August 2022: Wegovy and Ozempic were added to the FDA Drug Shortage List due to a demand surge. 503A and 503B compounders permitted to compound semaglutide under the drug shortage exception.
• February 21, 2025: FDA declared the semaglutide injection shortage resolved. Established enforcement discretion periods: 503A pharmacies until April 22, 2025; 503B outsourcing facilities until May 22, 2025.
• February 24, 2025: Outsourcing Facilities Association filed suit challenging FDA’s determination (OFA v. FDA, 4:25-cv-00174, N.D. Tex.).
• April 22-24, 2025: 503A enforcement discretion period ended April 22; court denied OFA’s preliminary injunction April 24 — confirming enforcement could proceed.
• May 22, 2025: 503B enforcement discretion period ended. Routine compounding of essentially a copy of semaglutide injection products became a violation of the FD&C Act.
• September 2025: The FDA issued warning letters to compounders and telehealth platforms marketing GLP-1 products, focusing on both compounding practices and marketing conduct claiming equivalence to FDA-approved products.
• As of April 2026: Limited patient-specific 503A compounding may continue for patients with documented clinical needs not met by commercially available products. Mass compounding for general distribution is prohibited. Rybelsus (oral semaglutide) was never on the shortage list and is not affected by these compounding restrictions.

The quality data from the compounding period — including instances of semaglutide samples testing at alarming impurity levels (one sample documented at 54.6% impurities with only 17% semaglutide by HPLC) and widespread potency discrepancies — demonstrates precisely why rigorous pharmaceutical analytical testing matters for any semaglutide product.

Semaglutide Analytical Testing Methods: Quick Reference

Method	What it detects	ICH/USP guideline	Key specification	Application stage
RP-HPLC/UHPLC-UV	Purity, related substance impurities, degradation products; individual and total impurities	ICH Q2(R1) validation; ICH Q3 impurities; ICH Q6B	DS: >/=98% purity; individual impurities typically <0.1-0.2%; synthesis-related impurity profiles differ for recombinant vs. synthetic	DS/DP release; stability-indicating; incoming QC
UHPLC-MS / HRMS	Identity confirmation by accurate mass; impurity characterization; sequence variants; N-terminal modifications; adduct detection	ICH Q6B; USP <1030>	MW: 4113.58 Da; [M+4H]4+ at m/z 1029.3 confirmed; characterize synthesis-related vs. fermentation-related impurities per manufacturing route	DS identity; impurity characterization; recombinant vs. synthetic comparison
LC-MS/MS (bioanalysis)	Semaglutide plasma/urine concentration for PK studies; metabolite identification	FDA/EMA bioanalytical method validation (2018); ICH M10	LLOQ ~0.1-1 ng/mL (injectable); <0.5 ng/mL for oral (lower Cmax); accuracy +/-15%; CV <15%	PK/PD studies; clinical trials; ADME; bioavailability (SC ~89%; oral ~0.8%)
SEC-MALS	Aggregates, oligomers, high-MW species; monomer purity	ICH Q6B; USP <1127>	HMWS typically <1-2% for release; size exclusion + multi-angle light scattering for absolute MW	DS/DP characterization; aggregation in stability; formulation screening
SNAC analysis (Rybelsus only)	SNAC identity and quantity in Rybelsus finished product; co-formulation consistency	ICH Q2(R1); per product specification	Per product specification; SNAC must be quantified separately from semaglutide	Rybelsus DP release; formulation development; absorption enhancer QC
Functional GLP-1 receptor binding activity confirms biological integrity beyond structural identity	Absence of viable microorganisms in the injectable product	ICH Q6B; USP <1033>	Per product specification, SNAC must be quantified separately from semaglutide	DS/DP release; stability (potency retention); biosimilar/follow-on comparability
Bacterial endotoxins (BET/LAL)	Gram-negative bacterial endotoxins — mandatory safety test for all injectables	USP <85>; Ph. Eur. 2.6.14	<1.0 EU/mL for parenteral products; gel-clot, turbidimetric, or chromogenic LAL method	Ozempic/Wegovy DP release; compounding QC — required for every injectable batch
Sterility testing	Anti-drug antibodies (ADAs), neutralizing antibodies (NAbs); titer and isotyping	USP <71>; Ph. Eur. 2.6.1	No growth in 14-day incubation (SCDM 20-25C; FTM 30-35C)	Ozempic/Wegovy DP release; compounding product release
Stability testing	Degradation under thermal, photolytic, oxidative, hydrolytic stress; shelf-life determination	ICH Q1A(R2); ICH Q5C for biologics	Ozempic/Wegovy: 2-8C refrigerated; Rybelsus: room temperature up to 30C; stability optimum pH 7.4-7.8	DS/DP development; shelf life; forced degradation to identify degradation pathways
Immunogenicity (ADA)	Per product specification, cell-based cAMP assay or receptor binding assay	ICH S6(R1); FDA immunogenicity guidance	Tiered approach: screening ECL/ELISA, confirmatory competitive inhibition, neutralization assay	Clinical trials (SUSTAIN, STEP, SOUL, SELECT, FLOW programs); pharmacovigilance

Key Test Categories in Detail

Drug Substance Purity and Impurity Analysis

For injectable semaglutide (Ozempic/Wegovy), RP-HPLC purity analysis uses wide-pore stationary phases. Recombinant semaglutide’s impurity characterization must address the yeast expression host cell protein (HCP) burden, host cell DNA, and process-related impurities from fermentation and purification — characterized using HCP ELISA, qPCR for residual DNA, and LC-MS/MS for process chemical residues. These analyses are fundamentally different from those applied to synthetic compounded semaglutide.

For synthetically produced semaglutide (all compounded products), impurity analysis must characterize: deletion sequences (peptides missing one or more amino acid residues); insertion sequences; amino acid substitution variants; diastereomers and epimers from racemization during synthesis; C18 fatty acid-related impurities (incomplete acylation, deprotection side products); and HPLC-related N-terminal modification products. Independent testing during the compounding period documented N-terminal histidine modifications as a widespread impurity in compounded semaglutide, not present in the Novo Nordisk branded product.

Bioanalytical Testing: LC-MS/MS for Pharmacokinetics

Injectable semaglutide LC-MS/MS bioanalysis uses the [M+4H]4+ precursor at m/z 1029.3 as the dominant analytical signal, with liraglutide commonly used as internal standard. Validated methods using Peptide CSH C18 columns (300 angstrom pore) with aqueous formic acid/acetonitrile gradients achieve LLOQ of ~0.1-1 ng/mL in plasma, sufficient for the therapeutic concentrations achieved in the SUSTAIN (diabetes) and STEP (obesity) clinical programs and for the long-tail PK characterization of semaglutide’s multi-week elimination profile (half-life ~165-183 hr).

Oral semaglutide bioanalysis (Rybelsus) requires significantly more sensitive methods due to the low oral bioavailability (~0.8% in humans). Post-oral dose peak plasma concentrations are approximately 100-fold lower than those achieved with subcutaneous dosing at equivalent semaglutide mass. Bioanalytical methods for the SOUL pharmacokinetic sub-studies used platforms achieving LLOQ <0.5 ng/mL, with careful method development to exclude SNAC interference in the biological matrix.

Stability Testing

Stability testing for semaglutide must account for its pH sensitivity: semaglutide is highly stable at pH 7.4-7.8 but degrades significantly below pH 7.0, particularly in the presence of phenol (a common injectable formulation preservative). This pH-dependent instability was characterized using RP-UPLC and LC-HRMS to identify key degradation pathways, including: oligomer formation at low pH; oxidation (particularly of the fatty acid chain); hydrolysis of the linker connecting the fatty acid to the peptide backbone; and proteolytic fragmentation. Stability protocols per ICH Q1A(R2) must include studies at 25°C/60% RH (long-term, zone I/II) and 40°C/75% RH (accelerated), with stability-indicating methods demonstrating separation of all identified degradation products from the main peak.

Injectable Safety Testing: Endotoxins and Sterility

Ozempic and Wegovy are subcutaneously injected products — meaning bacterial endotoxins testing (BET) and sterility testing are mandatory for every batch of finished drug product. BET by LAL per USP <85> must confirm endotoxin below 1.0 EU/mL. Sterility per USP <71> confirms absence of viable microorganisms after 14-day incubation. For compounded injectable semaglutide, absence of validated BET and sterility testing in many compounding operations was a documented quality risk that contributed to FDA adverse event reports.

Immunogenicity Testing

As a modified peptide with non-natural amino acid substitutions and fatty acid modifications, semaglutide has potential immunogenic risk. Clinical data from the SUSTAIN diabetes program and STEP obesity program showed low rates of ADA development (3-7% of patients across trials), with most ADAs being non-neutralizing and not associated with clinically meaningful reductions in efficacy. Immunogenicity testing follows a tiered approach: ECL or ELISA screening for ADA presence, competitive inhibition confirmatory assay, and cell-based neutralization assay for NAb characterization. For the expanded semaglutide clinical programs (SELECT, SOUL, FLOW trials), immunogenicity monitoring data confirmed the consistent, low immunogenicity profile across indications and formulations.

Semaglutide Clinical Trials and Outcomes Supporting Expanded Testing Needs

Semaglutide’s expanding clinical portfolio has generated one of the most extensive testing frameworks for any individual drug molecule:

• SUSTAIN program (Ozempic, T2D): Phases 1-10 clinical trials establishing once-weekly injectable semaglutide’s glycemic efficacy. SUSTAIN 6 demonstrated a 26% MACE reduction in T2D patients with high CV risk (basis for the CV indication in Ozempic’s original label).
• STEP program (Wegovy, obesity): Four Phase 3 trials demonstrating 15-17% mean weight loss with once-weekly 2.4 mg semaglutide. STEP trials provided the basis for Wegovy’s obesity approval.
• SELECT trial (Wegovy, cardiovascular, March 2024): 17,604 patients with CVD and obesity/overweight (no diabetes); 20% reduction in MACE vs. placebo; basis for Wegovy’s cardiovascular indication — the first weight-loss medication approved to reduce cardiovascular risk.
• FLOW trial (Ozempic, CKD, January 2025): 3,533 patients with T2D and CKD; 24% reduction in the composite of kidney disease progression, kidney failure, and CV death; basis for Ozempic’s CKD indication.
• SOUL trial (Rybelsus, cardiovascular, October 2024): 9,650 patients with T2D and ASCVD/CKD; 14% MACE reduction with once-daily oral semaglutide 14 mg; basis for Rybelsus’s cardiovascular indication.
• OASIS 4 (Rybelsus, obesity, December 2025): 71-week Phase 3 trial in adults with obesity using once-daily oral semaglutide 25 mg; basis for Rybelsus obesity indication — making it the first oral GLP-1 RA approved for obesity.

Finding Accredited Semaglutide Testing Laboratories

Semaglutide testing requires laboratories with specific expertise in: wide-pore RP-HPLC method development for lipidated peptides; recombinant biopharmaceutical characterization (HCP, residual DNA) for injectable products; synthetic peptide impurity analysis for research-grade and compounded products; sensitive LC-MS/MS bioanalysis at sub-ng/mL levels; SNAC analysis for Rybelsus; and ICH-compliant stability programs.

ContractLaboratory.com connects pharmaceutical companies, CROs, and research organizations with accredited pharmacology and drug development testing laboratories and biopharmaceutical specialists. See also our biopharmaceutical potency testing guide and the companion article on tirzepatide testing. Submit a testing request or contact our team for guidance.

Frequently Asked Questions About Semaglutide Testing

Conclusion

Semaglutide’s evolution from a single injectable diabetes drug to a multi-formulation, multi-indication therapeutic platform — spanning type 2 diabetes, obesity, cardiovascular risk reduction, chronic kidney disease, and MASH — has generated one of the most complex analytical testing landscapes for any pharmaceutical molecule. The fundamental distinction between recombinant yeast-expressed semaglutide (Ozempic, Wegovy, Rybelsus) and synthetic SPPS-produced compounded semaglutide creates testing requirements that cannot be interchanged. Rybelsus’s SNAC co-formulation requires entirely separate analytical approaches from the injectable products. And the complete closure of the compounding market has redirected the testing audience back to pharmaceutical development, biosimilar research, and clinical bioanalytical support.

ContractLaboratory.com connects organizations requiring semaglutide testing with accredited pharmaceutical testing laboratories experienced across the full testing spectrum — from RP-HPLC purity analysis and LC-MS/MS bioanalysis through injectable safety testing, stability, immunogenicity, and specialized oral formulation analytics. Submit a testing request or contact our team.